S1P Receptor Modulators Improve Clinical Outcomes in Ulcerative Colitis: A Stratified Meta-Analysis By Prior...

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), involves chronic immune-mediated inflammation.
• Sphingosine-1-phosphate (S1P) receptor modulators represent a novel therapeutic class targeting immune cell trafficking.

Purpose of the Study:

• To systematically review and meta-analyze the efficacy and safety of S1P receptor modulators in adult IBD patients.
• To assess the impact of baseline characteristics on treatment outcomes.

Main Methods:

• Systematic literature search of MEDLINE, PubMed, Web of Science, and Cochrane CENTRAL up to January 1, 2024.
• Inclusion of randomized controlled trials (RCTs) evaluating S1P modulators in adult IBD patients.
• Meta-analysis using inverse variance random-effects models with stratified analyses.

Main Results:

• S1P modulators significantly improved clinical remission in both induction (RR: 2.22) and maintenance (RR: 2.79) phases compared to placebo.
• Efficacy was notable in UC patients, with higher induction remission rates (RR: 2.69).
• Consistent efficacy observed across disease locations, corticosteroid use, and baseline Mayo scores; greater benefits seen in anti-TNF-naive patients. Etrasimod showed superior maintenance remission rates over ozanimod.
• Secondary outcomes, including endoscopic and histologic remission, were significantly improved. Adverse events were more frequent but serious events, infections, mortality, and cardiac events were comparable.

Conclusions:

• S1P receptor modulators demonstrate significant efficacy in improving remission rates and secondary outcomes for UC patients.
• The safety profile appears generally favorable, though further investigation is warranted for Crohn's disease.
• Etrasimod and ozanimod show promise, with etrasimod demonstrating higher maintenance remission rates in this analysis.